Benefits
Neuraminidase inhibition (anti-influenza mechanism)
Isenolic 8% reduced neuraminidase activity by up to 64% in vitro vs oseltamivir's (Tamiflu®) 88% inhibition — the same enzyme target recommended by WHO for viral infection management. Neuraminidase disassembles new flu virions from infected host cells, allowing them to spread to new cells. Inhibiting it prevents virus liberation and subsequent proliferation. Natural alternative or complement to oseltamivir.
Dose-dependent anti-influenza activity
Isenolic® showed dose-dependent anti-influenza activity in vitro, with IC50 values of 65.5 µg/ml (8% formulation) and 171.4 µg/ml (4% formulation) for influenza virus inhibition. The 8% formulation was approximately 2.6× more potent than the 4% formulation — supporting the higher-concentration version for symptomatic relief vs the 4% version for prevention.
Cell viability protection during infection
Pre-treatment with 8% Isenolic at 100 µg/ml preserved 72.9% cell viability post-influenza infection in MDCK-SIAT1 cells (a standard in vitro flu infection model). Direct cellular protection complements the neuraminidase inhibition mechanism — suggesting Isenolic helps prevent infection establishment as well as limiting virus spread once infection has occurred.
Multi-target antiviral mechanism
Beyond neuraminidase inhibition, ELA directly penetrates cells and blocks the entry of specific viruses — effectively putting the brakes on the viral life cycle at multiple stages. The multi-target mechanism is harder for viruses to develop resistance against vs single-target drugs like oseltamivir, addressing a growing concern about influenza antiviral resistance.
Antioxidant and immune support
Several studies report ELA provides antioxidant effects, promoting broader immunity beyond direct antiviral activity. Olive leaves have been related to multiple positive effects on the immune system, particularly against microbial threats. Reinforces the broader 'support immune system during respiratory illness season' positioning alongside the acute symptomatic use.
Traditional medicinal precedent
Olive leaf has been used for medicinal purposes since ancient Egypt — for fever combat and cold treatment. Ancient Greek culture also used olive leaf to lower fever. The long traditional use combined with modern characterized mechanisms (neuraminidase inhibition, multi-target antiviral activity) supports Isenolic's positioning as both traditionally validated and scientifically substantiated.
Sustainable and locally sourced
Pharmactive sources Isenolic from olive leaves locally in Spain — where olive cultivation has thousands of years of history. The extraction uses a patented, environmentally sound method that preserves extract quality while reducing waste. The local sourcing also supports traceability and quality control vs international supply chains where olive leaf extract adulteration is common.
Mechanism of action
Viral neuraminidase enzyme inhibition
Neuraminidase is a key enzyme on the surface of the influenza virus that disassembles new virions from infected host cells, allowing them to spread. Elenolic acid inhibits this enzyme — the same target as the pharmaceutical drug oseltamivir (Tamiflu®). WHO recommends neuraminidase inhibitors as a primary strategy for viral infection management.
Direct cellular entry blockade
Elenolic acid directly penetrates host cells and blocks the entry of specific viruses at the receptor-binding step. This mechanism prevents infection before it establishes, complementing the neuraminidase inhibition that limits spread of already-infected cells. The dual-stage activity makes Isenolic potentially effective both as prevention and acute treatment.
Antimicrobial spectrum
Olive tree extracts have been documented sources of antimicrobial activity across viral, bacterial, and fungal pathogens since antiquity. Modern research has confirmed broad-spectrum activity. The mechanism supports Isenolic's positioning beyond influenza to broader respiratory tract infections, though influenza is the best-characterized indication.
Antioxidant ROS scavenging
ELA and other olive leaf phenolic compounds have direct antioxidant activity, scavenging reactive oxygen species (ROS) generated during viral infections. ROS contribute to inflammation and tissue damage during respiratory illness — antioxidant activity supports symptom reduction beyond pure antiviral mechanisms.
Clinical trials
In vitro comparison of Isenolic® (4% and 8% ELA formulations) vs oseltamivir (Tamiflu®) for anti-influenza activity. Tests included HPLC-MS characterization, cytotoxicity, viral neuraminidase inhibitor activity, and cell viability protection against influenza infection in MDCK-SIAT1 (sialic acid overexpressing Madin-Darby Canine Kidney) cells. Published 2021 (PMID 34839747).
Not applicable — in vitro study using MDCK-SIAT1 cell line.
Isenolic 8% formulation showed dose-dependent anti-influenza activity with IC50 of 65.5 µg/ml (vs 171.4 µg/ml for 4% formulation). Neuraminidase inhibition up to 64% (vs 88% for oseltamivir). Pre-treatment with 8% Isenolic at 100 µg/ml preserved 72.9% cell viability post-infection. Established Isenolic as a promising natural alternative or complement to existing influenza neuraminidase inhibitor treatments.
Double-blind, randomized clinical study (Australian/New Zealand Clinical Trials Registry trial ID 378823). Maximum 4-month participant duration with two groups (active ingredient vs placebo). Isenolic standardized for ELA at 150 mg/capsule, 2 capsules/day (300 mg total) taken immediately upon symptom onset.
Healthy adults experiencing cold/flu symptom episodes. 2-week supply (28 capsules) per illness event.
Registered with formal trial protocol on the Australian New Zealand Clinical Trials Registry. Trial protocol evaluated symptom duration, severity, and frequency of respiratory illness events with Isenolic vs placebo over the 4-month study window. Outcomes contribute to the Isenolic evidence base for symptomatic respiratory illness management.
Independent randomized controlled trial of olive leaf extract (containing 100 mg oleuropein equivalent, 20 g olive leaf) for upper respiratory illness (URI) in high school athletes during competitive season. 9-week intervention. Published in Nutrients (PMID 30986973).
32 high school students competing at elite sports level. 9-week intervention during competitive season.
No significant difference in URI incidence between olive leaf extract and placebo groups (OR 1.02, 95% CI 0.21-4.44). However, significant 28% reduction in sick days when supplemented with olive leaf extract (OR 0.72, 95% CI 0.56-0.93, p=0.02). Effect on duration/severity rather than incidence is consistent with the Isenolic positioning for symptomatic relief once illness has begun.